Stockwinners Market Radar for April 29, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:41 EDT Samsung says Display segment results declined in Q1 on weak seasonality - The company reported Display segment revenue of KRW 5.39T vs. KRW 6.61T last year and operating profit of KRW 0.34T vs. KRW 0.78T last year. In Display Mobile, the company states: "Results declined due to weak seasonality and intensifying sales competition. However, we accommodated the launches of a major customer's new high-end smartphones with timely supply of flexible displays. For rigid displays, our utilization rate improved as a result of our widened sales base." Q2 Mobile Display outlook: "Expect sales to increase ahead of the launch of our major customer's new foldable phone and on growing demand for IT products, but intensifying competition among panel makers is likely to limit earnings growth." FY24 Mobile Display outlook: "Anticipate moderate market growth with the OLED penetration rate to keep rising in particular. Maintain our competitive edge in flexible displays and expand sales through our differentiated technology related to low-power consumption, enhanced durability, etc. Continue to replace LCD in the rigid display smartphone market by accelerating cost reductions."

19:33 EDT Four Corners Property Trust acquires Urgent Care facility for $6.6M - Four Corners Property Trust announces the acquisition of a Patient First Urgent Care property for $6.6 million. The property is located in a highly trafficked corridor in Pennsylvania under a triple net lease with approximately ten years of term remaining. The transaction was priced at a 7.1% cap rate on rent as of the closing date and exclusive of transaction costs.

18:42 EDT Genmab-Pfizer's gains full FDA approval for TIVDAK in Metastatic Cervical Cancer - Pfizer (PFE) and Genmab A/S (GMAB) "announced the FDA approves the supplemental Biologics License Application granting full approval for TIVDAK, or tisotumab vedotin-tftv, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The approval is based on results from the global, randomized, Phase 3 innovaTV 301 clinical trial, which met its primary endpoint, demonstrating overall survival benefit in adult patients with previously treated recurrent or metastatic cervical cancer treated with TIVDAK compared to chemotherapy. Secondary endpoints of progression-free survival (PFS) and confirmed objective response rate were also met. In October 2023, results from the innovaTV 301 study were presented during the Presidential session at the European Society of Medical Oncology Congress. The innovaTV 301 study demonstrated a 30% reduction in the risk of death compared to chemotherapy (hazard ratio: 0.70, two-sided p=0.0038)i. Median OS for patients treated with TIVDAK was 11.5 months versus chemotherapy 9.5 months."

17:50 EDT Minerals Technologies' BMI unit competes talc asset sales to Riverspan for $32M - Minerals Technologies announced that its subsidiary, Barretts Minerals BMI, has completed the sale of all the talc assets to Riverspan Partners for $32M. The go-forward company will conduct business under the Barretts Minerals brand. The United States Bankruptcy Court for the Southern District of Texas approved the sale, which includes an agreement to assume certain Assumed Liabilities, on March 25, as part of the ongoing Chapter 11 process of Barretts Minerals and Barretts Ventures Texas together, BMI . Proceeds from the sale will be used to fund BMI's ongoing Chapter 11 case including the repayment of its debtor-in-possession funding and the anticipated creation of a section 524 g trust.

17:26 EDT Adamas One discloses Nasdaq listing non-compliance notice - Adamas One reports that it has a hearing scheduled for May 30, 2024 before a Nasdaq Hearings Panel regarding its plan to regain compliance with Nasdaq Listing Rule 5550(a)(2). On April 23, 2024, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company of its noncompliance with two additional rules: (1) Nasdaq Listing Rule 5250(f) for the Company's failure to pay its Nasdaq annual listing fee; and (2) Nasdaq Listing Rule 5250(c)(1) for the Company's previously disclosed failure to timely file its (a) Annual Report on Form 10-K for the year ended September 30, 2023 and (b) Quarterly Report on Form 10-Q for the period ended December 31, 2023. The Company's violations of the Fees Rule and the Filings Rule serve as an additional basis for delisting the Company's securities from Nasdaq and the Panel will consider these matters at the May 30th hearing."

16:52 EDT Recon Technology receives delisting determination from Nasdaq, submits appeal - Recon Technology announced that it has received a staff determination letter from Nasdaq notifying the company of the the determination to delist the company's securities from Nasdaq because the company currently fails to satisfy the requirement that the closing bid price of its securities remain at $1.00 or higher as required by Nasdaq Listing Rule 5810. The company had received a period of 180 calendar days and a second period of an additional 180 calendar days to return to compliance with the minimum bid price rule, which compliance period expired on April 22. As of April 22, the company did not regain compliance with Listing Rule 5550 which was triggered since the bid price of the company's listed securities had closed at less than $1.00 per share over the previous 30 consecutive business days. The company has already appealed the determination to a hearings panel, and separately the company expects the recently approved consolidation of its Class A ordinary shares will take effect on May 1. The company's hearing request submission will stay the suspension of the company's securities and the filing of the Form 25-NSE pending the panel's decision.

16:47 EDT Direct Selling Acquisition announces delisting from NYSE - Direct Selling Acquisition announced that it has received a notice letter from the NYSE that the staff of NYSE Regulation has determined to commence proceedings to delist its Class A common stock, par value $0.0001 per share and units, each consisting of one share of Class A common stock and one-half of one redeemable warrant from NYSE. Trading in the Company's Securities will be suspended, effective at the close of trading on April 29. The Company's Class A Common Stock and Units are expected to open on the OTC Markets' Pink Market on April 30, 2024 under the symbols "DSAQ" and "DSAQ.U", respectively. The Company has submitted an application to have its securities quoted on the OTCQX Marketplace. The Company cannot provide any assurance that the Securities will commence or continue to trade on this market, whether broker-dealers will continue to provide public quotes of the Securities on this market, whether the trading volume of the Securities will be sufficient to provide for an efficient trading market or whether quotes for the Securities will continue on this market in the future. The Company previously announced its intention to voluntarily delist its Securities from NYSE.

16:36 EDT Yum China CEO says 'solid sales growth in the first quarter' - Joey Wat, CEO of Yum China, commented, "We achieved solid sales growth in the first quarter with total revenues hitting an all-time high. Our core operating profit grew modestly from last year's high base and EPS was up double digits excluding foreign currency. Meanwhile, we are marching forward with our expansion initiatives in a disciplined manner, bringing our total store count to a milestone of 15,000 stores. Besides investing in our organic growth, we boosted capital returns to shareholders to a new record level. Remaining agile, we are continuously learning and innovating to embrace new consumer trends in changing market conditions. Our amazing high-ticket products, such as our KFC beef burger and whole chicken, grew by double digits in the quarter. Our six-year old iconic Crazy Thursday campaign and limited-time-offer of all-you-can-eat at Pizza Hut continue to excite customers and drive incremental traffic. By optimizing delivery strategies, KFC expanded its market share on the aggregator platforms and drove double-digit growth in delivery sales. At the same time, our relentless pursuit of greater operational efficiency from store to supply chain further fortifies our resilience. This has empowered us to pass on savings to our customers and other stakeholders." Wat continued, "Operating under a near-term challenging environment, we will remain laser-focused on understanding and capturing the evolving needs of consumers to continually connect with them. Looking toward the future, we are absolutely confident in seizing China's vast opportunities. We are expanding addressable market through a multifaceted approach with flexible store formats, strategic franchising and a range of exciting products across price points. With these actions underway, we believe we are well-poised to sustain strong growth and create long-term value for our shareholders."

16:34 EDT Park-Ohio backs FY24 guidance - The company states: "For 2024, we continue to expect revenue growth in the mid-single digit range year-over-year, driven by continued strong demand in most end markets in Supply Technologies and Assembly Components, and the strength of our backlog in Engineered Products. In addition, we continue to expect year-over-year improvement in EPS and EBITDA."

16:32 EDT LL Flooring provides update on strategic alternatives review - LL Flooring (LL) "provided an update on its previously announced strategic alternatives review process and separately announced a cooperation agreement signed with Live Ventures Incorporated (LIVE) a diversified publicly traded holding company, and Isaac Capital Group regarding director nominations to the Company's Board of Directors. As part of the Company's previously announced strategic alternatives review process, the Company's Board has received a non-binding proposal to acquire all of the outstanding shares of the Company for $2.50 per share in cash, which remains subject to completion of certain financing. Consistent with its fiduciary duties and in consultation with its financial and legal advisors, the LL Flooring Board remains in constructive discussions and is currently negotiating this latest proposal, which has not yet been accepted by the Board. The LL Flooring Board is committed to a fair process for all interested parties and will continue to thoroughly review any credible proposal received to determine the course of action that it believes is in the best interests of the Company and all of its shareholders. There can be no assurance that the Company's strategic alternatives process will result in LL Flooring pursuing any particular transaction or other strategic outcome. The Company has not set a timetable for completion of this process, and it does not intend to disclose further developments unless and until it determines that further disclosure is appropriate or necessary. The Company has separately entered into a cooperation agreement with Live Ventures and Isaac Capital Group with regard to director nominations and the voting of their aggregate 3.8% ownership of LL Flooring common stock at the Company's upcoming Annual Meeting of Stockholders set for July 10, 2024. Isaac Capital Group had previously nominated three individuals to stand for election to the LL Flooring Board at the Annual Meeting and, in connection with the cooperation agreement, has now withdrawn these nominations and will vote its shares in support of the Company's directors. The full cooperation agreement, which includes customary standstill, voting and confidentiality commitments, among other provisions, will be filed with the U.S. Securities and Exchange Commission."

16:27 EDT Clearwater Paper CEO says customer destocking now in the past - "We expect continued strength in our tissue performance this year and a recovery in paperboard demand as we believe customer de-stocking is now largely behind us. We are also looking forward to completing the Augusta acquisition and personally welcoming the Augusta team to Clearwater Paper," said CEO Arsen Kitch.

16:25 EDT Joby Aviation expands California manufacturing facility - Joby Aviation announced it has broken ground on the expansion of its Pilot Production Line in Marina, California. The expansion will more than double Joby's manufacturing footprint at the Marina Municipal Airport and is expected to begin operations next year. The expanded facility is designed to support a target production rate of 25 aircraft per year and will also house a range of key operations facilities, including an expanded pilot training and flight simulation center as well as aircraft maintenance facilities that are designed to support the scaling of Joby's commercial operations. "This facility will play a foundational role in our future success and it is a privilege to once again be growing our footprint and our workforce in California. I am grateful to the local community and our many supporters who have advocated on our behalf to reach this point and to Toyota for everything they continue to do to make manufacturing a success at Joby," said JoeBen Bevirt, Founder and CEO of Joby.

16:25 EDT Sensata announces CEO transition, names Elliott Investment's Eyler to board - Sensata Technologies "announced that Jeff Cote, CEO, has informed the Board of Directors of his intention to retire as CEO and President and step down as a member of the Sensata Board, effective April 30, 2024. The Board of Directors has appointed Martha Sullivan as Interim President and CEO and has established a CEO Search Committee to identify a new permanent CEO. In addition, following a constructive dialogue with Elliott Investment Management L.P. , Sensata has appointed Phillip Eyler to the Company's Board. Mr. Eyler will serve on the CEO Search Committee and the Nominating and Governance Committee when he joins the Board on July 1, 2024. With the appointment of Eyler, Sensata's Board will consist of eleven directors, ten of whom are independent. The Company has entered into a Cooperation Agreement with Elliott, as well as an Information Sharing Agreement to facilitate an ongoing dialogue between Elliott and the Board as both seek to drive sustainable value creation for all Sensata shareholders. The Cooperation Agreement contains customary standstill, voting, and other provisions."

16:22 EDT Simply Good Foods to acquire Only What You Need, OWYN, for $280M in cash - The Simply Good Foods Company announced that the companies have entered into a definitive agreement under which Simply Good Foods will acquire OWYN for $280M in cash. Only What You Need is the fastest growing1 RTD protein shake brand in the market and enhances Simply Good Foods' portfolio with further diversification and provides the Company with a greater presence within the RTD protein shake segment. The addition of OWYN, which Simply Good Foods will acquire from existing investor United Nutritional Brands, an affiliate of Purchase Capital LLC, and other minority investors, builds on Simply Good Foods' leadership position within the nutritional snacking category. "The acquisition of Only What You Need is strategically compelling as it brings a third, complementary brand to Simply Good Foods and further enhances our presence in the fast-growing RTD shake segment," said Geoff Tanner, President and Chief Executive Officer of Simply Good Foods. "Additionally, OWYN reaches a new, incremental consumer segment which strengthens our category leading presence with retail customers. We are confident our go-to-market capabilities will accelerate profitable growth through accelerated distribution gains, increased household penetration and leveraging our cost-efficient supply chain. We'll also look to leverage the knowledge of our collective R&D teams to continue to enhance core product performance and unlock white-space growth opportunities in other forms. Over the last few years, OWYN's net sales growth rate has been top tier within the nutritional snacking category. In 2024, we expect OWYN will achieve net sales of approximately $120 million.2 They have strong relationships with blue-chip customers in both measured and natural channels and have an impressive, profitable and growing Ecommerce business. Upon the transaction's closing, we look forward to working with Mark Oliveri, President and Chief Executive Officer of OWYN, and his leadership team. As we proceed through integration and become one Company, Mark will continue in his role and lead the OWYN team as we look to grow the brand." "Since OWYN's launch in 2017, our goal has been to bring truth and transparency to everything we do while providing the best tasting RTD protein shakes in the market," said Mark Oliveri, President and Chief Executive Officer of OWYN. "This transaction is a continuation of our mission as Simply Good Foods is also committed to providing its consumers with quality products focused on high protein, minimal sugars and low levels of net carbohydrates. I'm extremely proud of everything the OWYN team has accomplished in establishing a $120M dollar brand in such a short time," Oliveri concluded.

16:22 EDT Hologic to acquire Endomagnetics for $310M - Hologic "announced that it signed a definitive agreement to acquire Endomagnetics Ltd (Endomag(R)), a privately held developer of breast cancer surgery technologies, for approximately $310 million, subject to working capital and other customary closing adjustments. Endomag, which is based in Cambridge, United Kingdom, develops and sells breast surgery localization and lymphatic tracing technologies. Its products include the Magseed(R) marker for magnetic tissue localization before surgery, the Magtrace(R) lymphatic tracing injectable for breast cancer staging and the Sentimag(R) platform, which supports both localization and lymphatic tracing. Endomag generated approximately $35 million of revenue in calendar 2023. The acquisition is expected to be slightly dilutive to Hologic's non-GAAP earnings per share in fiscal 2024, break even in 2025 and accretive thereafter. Completion of the acquisition is subject to customary closing conditions, including regulatory approvals."

16:19 EDT Rocky Brands annoucnes debt refinancing - Rocky Brands "announced the signing of a definitive debt refinance agreement with Bank of America, as agent. The new agreement, which amends and restates the Company's existing revolving credit facility, will serve to enhance the Company's cash flow and liquidity profile while permitting a more simplified capital structure. The upsized, amended and extended ABL facility, agented by Bank of America, is comprised of a $175 million revolving credit facility and a $50 million term facility, amending and restating the Company's existing $175 million revolving credit facility with Bank of America. Proceeds from the refinance were used to retire the Company's existing senior secured term loan facility agented by TCW Asset Management Company, LLC as of April 26, 2024. The combined transactions are expected to generate net savings of approximately $2.9 million for the remainder of 2024, offset by fees and amortization associated with the retirement of the senior secured term loan facility of approximately $2.6 million. In 2025, the combined transactions are expected to generate a combined annualized savings of approximately $4.4 million."

16:19 EDT Biote enters into settlement with founder Gary Donovitz - biote Corp "announced it has entered into a definitive settlement agreement that concludes outstanding litigation with Dr. Gary S. Donovitz, founder and stockholder of Biote. The Settlement Agreement includes a mutual release of all claims relating to litigation between Donovitz and Biote; the termination of the founder advisory agreement by and between Donovitz and BioTE Medical, LLC; two year non-compete and non-solicitation agreements for Donovitz; and a voting agreement with customary terms acceptable to the Company. Additionally, Biote will repurchase all 18.4 million Biote shares beneficially held by Donovitz."

16:17 EDT Rayonier Advanced Materials to suspend Temiscaming High Purity Cellulose Plant - The company states: "Rayonier Advanced Materials is announcing that, effective July 2, 2024, it will suspend operations at its Temiscaming High Purity Cellulose plant for an indefinite period. As previously communicated, the Company remains committed to operating its assets profitably. Given current market conditions and high capital and fixed costs associated with the HPC plant, this decision will help mitigate the plant's ongoing operating losses and improve the Company's consolidated free cash flow. Today's announcement is aligned with the Company's focus on improving its balance sheet, leverage position and overall financial performance toward execution of its long-term growth strategy. The suspension, which will be carried out in a safe and environmentally sound manner, will result in a reduction of RYAM's annual global HPC production. The Temiscaming HPC facility has an annual production capacity of approximately 150,000 metric tons, with roughly 30 percent historically dedicated to specialty cellulose materials. The Company will be working directly with its customers to support their specialty cellulose needs in both the short- and long-term. Today's announcement will result in approximately 275 layoffs."

16:14 EDT Kopin enters into India defense market - The company states: "Kopin Corporation has further expanded its customer base by receiving a third production order for its Organic Light Emitting Diode (OLED) microdisplays, for use in thermal imaging vision systems - both mounted and handheld for Indian Armed Forces. Under the terms of the latest production order for over 1,200 units, deliveries take place over a six-month time span. Kopin's highly efficient OLED microdisplays are ideal for portable thermal imaging vision systems, because of their ultra-compact size and low power, which makes them suitable for mobile battery-powered applications. The high-resolution display provided in this order will deliver essential information to end users and provide them with additional situational awareness and a performance advantage."

16:07 EDT Chegg names Nathan Schultz CEO - Chegg announced the appointment of Nathan Schultz as President and Chief Executive Officer, effective June 1. Schultz will succeed Dan Rosensweig, who will step up to the role of Executive Chairman after 14 years as CEO. Schultz is a veteran of Chegg and has served in multiple leadership roles over the last 16 years at the company. Early on he was responsible for Chegg's required materials offerings and was instrumental in shifting the company to a fully digital learning platform in his role as President of Learning Services. In 2022, he was elevated to the role of Chief Operating Officer, overseeing Chegg's learning services, including Chegg Study, Writing, and Math, and non-academic support, such as language learning and skills training. Under his leadership, Schultz led Chegg to embed AI into every facet of product development, specifically driving the formation of Chegg's unique and proprietary large language models that are the foundation for the company's new personalized learning experience.

16:04 EDT Paramount reports Q1 net operating cash flow $260M, free cash flow $209M

16:03 EDT Bloom Energy, Quanta Computer enter partnership - The company states: "Bloom Energy announced a groundbreaking partnership with Quanta Computer Inc. , a premier Taiwanese electronics manufacturer. The partnership adds another significant proof-point in Bloom Energy's capability to meet the ever-increasing time-to-power challenges of the burgeoning AI sector. The partnership arose from a critical challenge Quanta faced in powering its planned manufacturing expansion in Fremont, CA: the local utility company indicated it would take several years to provide the electricity required to fully power operations at the facility. With commitments to promptly deliver products to clients for expediting their AI infrastructure and services readiness, Quanta needed a clean and affordable solution to rapidly deliver reliable power. The power solution is a fully islanded microgrid, which will power Quanta Computer's operations around the clock, 24/7 365 days a year. By leveraging Bloom Energy's innovative and modular microgrid solution, Quanta is circumventing the lengthy delays and conditions associated with traditional utility constraints to maintain its competitive edge in the fast-paced Silicon Valley market."

16:00 EDT Paramount announces Bob Bakish to step down - The Board of Directors of Paramount Global announced that Bob Bakish, President and CEO, is stepping down from his role as CEO and from the Board of Directors. To lead and oversee the company moving forward, Paramount Global has established an Office of the CEO, consisting of three senior company executives: George Cheeks, President and CEO of CBS; Chris McCarthy, President and CEO, Showtime/MTV Entertainment Studios and Paramount Media Networks; and Brian Robbins, President and CEO of Paramount Pictures and Nickelodeon. Cheeks, McCarthy and Robbins will work closely with Naveen Chopra, CFO, and the Board of Directors. The Office of the CEO is working with the Board to develop a comprehensive, long-range plan to accelerate growth and develop popular content, materially streamline operations, strengthen the balance sheet, and continue to optimize the streaming strategy. The Board has great confidence in the leaders comprising the Office of the CEO, all of whom are senior creative executives and business leaders with a track record of success running meaningful businesses within Paramount Global. Shari Redstone, Chair of the Board, said: "Paramount Global includes exceptional assets and we believe strongly in the future value creation potential of the Company. I have tremendous confidence in George, Chris and Brian. They have both the ability to develop and execute on a new strategic plan and to work together as true partners. I am extremely excited for what their combined leadership means for Paramount Global and for the opportunities that lie ahead."

14:37 EDT Janone Inc trading resumes

14:31 EDT DXL Big + Tall announces strategic collaboration with Nordstrom - Destination XL Group (DXLG) announced a strategic collaboration with Nordstrom (JWN) which will launch on their digital platform. This collaboration marks a significant step in extending DXL's "fit" expertise and diverse style selection to a new segment of the underserved Big + Tall consumer. The alliance coincides with the launch of Nordstrom's new marketplace, designed to broaden their brand catalog to new audiences. As a key component of this expansion, DXL will bring its extensive collection of high-quality Big + Tall apparel to Nordstrom customers, further embodying the brand's commitment to DXL's "Wear What You Want" mission. Harvey Kanter, President and Chief Executive Officer of DXL, stated, "This collaboration with Nordstrom allows us to extend our "fit" expertise and unique styling to a new segment of Big + Tall customers. Together, we are not just expanding our reach; we are not just extending Nordstrom's current Big + Tall offerings, but enhancing the way Big + Tall apparel is viewed and purchased. Our mission is to provide every Big + Tall man with the freedom to choose his own style, and working with Nordstrom amplifies this commitment." Nordstrom's new marketplace is set to launch this April, with DXL's collection of brands.

14:01 EDT California New Car Dealers Association says Tesla sales 'may have peaked' - The California New Car Dealers Association released its California Auto Outlook covering Q1 of 2024 ."Californians' love affair with electric vehicle giant Tesla may have peaked. Tesla registrations are down again in The Golden State YTD, reporting a 7.8 percent dip (last quarter posted a 9.8 percent decline) amongst all brand registrations. Toyota showed significant gains among the top three California shareholder brands, increasing to 16.6 percent, as did Honda, capturing 10.5 percent of the market, while Tesla's numbers faltered (11.6 percent)," the report reads. The California New Car Dealers Association says traditional manufacturers are "stepping up to the plate," offering new plug-in hybrid hybrid, and battery electric vehicle models. This shift is evident in the sales of BEVs by traditional franchised dealerships, which have increased 14% compared to last year's figure, it notes. Reference Link

12:50 EDT Complete Solaria names T.J. Rodgers CEO, Brian Wuebbels COO - Complete Solaria announced that T.J. Rodgers will become the company's Chief Executive Officer. Rodgers said, "First, I would like to thank Chris Lundell, our current CEO, who came in at the board's request to stabilize the company during a stressful period of rapid headcount reduction. Chris will remain on the Company's board. Moving forward, I believe in the Company's mission and I will step up to the CEO job to use my experience at fund raising and M&A to help it succeed. That said, I will resign as CEO when one of two endpoints occurs: success, when we are on a solid economic footing and growing rapidly - or failure, when I believe that the chokehold our private equity debt holders have on us will prevent the company from ever being successful." Complete Solaria also announced the promotion of Brian Wuebbels, its current Chief Financial Officer, who also has an MBA and a degree in mechanical engineering, to the position of Chief Operating Officer reporting to Rodgers. Wuebbels said, "Last year, I made the decision to move on from Complete Solaria in order to take the next step in my career, but I agreed with T.J. Rodgers to stay behind for a quarter to make sure that CSLR's first full physical audit and SEC 10K report filing were on time and error-free. I now look forward to taking our solar operations to the next level in yield, quality and cycle time."

12:01 EDT AMC Entertainment falls -10.9% - AMC Entertainment is down -10.9%, or -37c to $3.04.

12:01 EDT Annovis Bio falls -69.5% - Annovis Bio is down -69.5%, or -$12.51 to $5.50.

12:00 EDT Philips rises 29.4% - Philips is up 29.4%, or $6.21 to $27.27.

11:20 EDT Microsoft makes Copilot available to all advertisers - Microsoft's AI assistant Copilot is now available for all advertisers across the Microsoft Advertising Platform, the company announced in a blog post. "The broader momentum we're seeing for advertising across Microsoft is being driven, in part, by increased volume and engagement on Microsoft Bing and Edge, and Copilot is playing an integral role. As we just reported in earnings, Bing reached over 140 million daily active users and we once again took share across Bing and Edge. Through innovation and partnerships, we're putting all our assets to work to deliver a meaningful alternative and real monetization opportunity for advertisers and publishers in this new era of AI. Microsoft Advertising is continuing to make strides in empowering businesses of all sizes to unlock the power and potential of this technology." The company added that "We believe that generative AI can unlock productivity, boost creativity, and provide a real-time intelligent assistant to help you achieve your advertising goals." Reference Link

10:28 EDT Annovis Bio Inc trading resumes

10:18 EDT KORE Group Holdings Inc trading resumes

10:03 EDT Kore names Ronald Totton as interim president and CEO to succeed Romil Bahl - KORE Group Holdings announced that Romil Bahl will be stepping down as President and CEO and that the company's Board of Directors has named Ronald Totton as the company's Interim President and CEO, effective May 3, 2024. Romil Bahl has served as KORE's President and CEO since 2017. Totton, who will succeed Mr. Bahl, brings nearly three decades of strategy, finance, sales, and leadership experience to the President and CEO role at KORE, including many years in the Technology, Media, and Telecoms sector. KORE's management change is not the result of any material or unexpected financial events.

10:01 EDT AMC Entertainment falls -8.4% - AMC Entertainment is down -8.4%, or -28c to $3.12.

10:01 EDT Deutsche Bank falls -9.9% - Deutsche Bank is down -9.9%, or -$1.75 to $16.02.

10:00 EDT Arcadium Lithium rises 13.0% - Arcadium Lithium is up 13.0%, or 51c to $4.38.

10:00 EDT Bakkt rises 2241.1% - Bakkt is up 2241.1%, or $8.96 to $9.36.

09:48 EDT Annovis Bio Inc trading halted, news pending

09:48 EDT AMC Entertainment falls -6.7% - AMC Entertainment is down -6.7%, or -23c to $3.18.

09:47 EDT Xperi rises 13.0% - Xperi is up 13.0%, or $1.29 to $11.24.

09:47 EDT Bakkt rises 2276.8% - Bakkt is up 2276.8%, or $9.10 to $9.50.

09:22 EDT Diana Shipping announces time charter contract for m/v Leto with ASL - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with ASL Bulk Shipping Limited, for one of its Panamax dry bulk vessels, the m/v Leto. The gross charter rate is US$16,000 per day, minus a 5% commission paid to third parties, for a period until minimum March 1, 2025 up to maximum April 30, 2025. The charter is expected to commence on May 2, 2024.

09:21 EDT Sintx Technologies, Prodways enter ceramic slurry supply, 3D printing agreement - SINTX Technologies and Prodways Printers SAS announce they have entered into a deep technical partnership and ceramic slurry supply agreement. SINTX and its subsidiary Technology Assessment and Transfer, Inc. will supply ceramic-filled printable slurries to Prodways and will assist in process development and customer support. The scope of collaboration will allow an end-to-end workflow collaboration on advanced technical ceramics, including in particular casting applications.

09:17 EDT Antelope Enterprise announces plan to launch energy transmission business - Antelope Enterprise Holdings announced that its plan to launch its energy transmission business. The Board appointed Huoyou Zhang as an Executive Director to the Company's Board of Directors, effective April 26, 2024, and Di Wu as a Director and President of its operating subsidiary to lead this new business. Also, Qiguo Wang resigned from the Company's Board, effective April 26, 2024, for personal reasons. The Company's new business of energy transmission is being operated via its wholly owned subsidiary, AEHL US LLC.

09:16 EDT Mullen Automotive announces CARB issued approval of EV trucks for HVIP - Mullen Automotive announces the California Air Resources Board, CARB, has approved the Company's all-electric Class 3 low cab forward, the 2024 Mullen THREE, for the Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project, HVIP. "California's HVIP approval for the 2024 Mullen THREE is a significant milestone making our Class 3 electric truck even more attractive and accessible to businesses seeking to electrify their fleets," said David Michery, CEO of Mullen Automotive.

09:08 EDT Allegiant Travel reports Q1 total system passengers down 1.1% y-o-y - Reports Q1 total system ASMs up 2.0%.

09:06 EDT FDA clears GE HealthCare's Portrait VSM for connected patient monitoring - GE HealthCare announced it has received 510(k) clearance from the United States Food and Drug Administration FDA for its Portrait VSM vital signs monitor that can provide clinicians with an accurate view of patient vital signs to support timely clinical decisions. As the next evolution of the DINAMAP legacy, Portrait VSM utilizes the SuperSTAT non-invasive blood pressure algorithm to provide precise and accurate measurement readings. Through its wireless connectivity and seamless EMR integration, the portable vital signs monitor was designed with the user workflows in mind, offering customized Early Warning Scores EWS and enabling care teams to focus on taking care of their patients by automating routine tasks. GE HealthCare's Reimagining Better Health study highlighted the burden of inputting and accessing data manually, with nearly half of clinicians reporting that medical technologies at their facilities do not seamlessly integrate with each other.* Portrait VSM offers workflow efficiencies and capabilities to support hospitals and care teams in navigating current challenges they're facing. Healthcare systems can incorporate and customize EWS protocols into the monitor view to help clinicians recognize the early signs of deterioration in patients and make timely interventions, while limiting manual calculations and transcription. To enable simplified rounding and help avoid delayed measurements, the Round Advisor feature also helps care teams manage and prioritize spot checks for multiple patients by assigning and tracking a sequence of care.

09:04 EDT Abbott's dissolving stent receives FDA approval for arteries below the knee - Abbott announced that the FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System, for people with chronic limb-threatening ischemia below-the-knee - BTK -. The Esprit BTK System is designed to keep arteries open and deliver a drug to support vessel healing prior to completely dissolving. The standard of care has been balloon angioplasty. However, blockages treated only with balloon angioplasty have poor short- and long-term results, and in many instances the vessels become blocked again, requiring additional treatment. The Esprit BTK System helps heal the vessel and provides support for approximately three years until the vessel is strong enough to remain open on its own. More than 20 million people in the U.S. are living with PAD and only 10% of those people have been diagnosed. CLTI is a serious form of PAD that occurs when arteries become clogged with plaque, preventing blood flow and oxygen from reaching the lower leg and foot.

08:59 EDT AIM ImmunoTech announces evaluation of first dose level in Phase 1b/2 study - AIM ImmunoTech (AIM) announced that it has taken an essential step forward in testing the combination of AIM's Ampligen and AstraZeneca's (AZN) anti-PD-L1 immune checkpoint inhibitor Imfinzi in the treatment of late-stage pancreatic cancer. Investigators at Erasmus Medical Center in the Netherlands have completed the safety evaluation of patients enrolled in the first dose level of the dose escalation design in the Phase 1b/2 study. The combination of Ampligen and Imfinzi was found to be generally well-tolerated with no severe adverse events or dose-limiting toxicities. Based on these positive results, escalation to the next dose will occur according to protocol design and AIM expects the next cohort of patients to begin dosing very soon. Subjects will be in treatment for up to 48 weeks, or until confirmed disease progression or another discontinuation criterion is met. They will be monitored for response according to Response Evaluation Criteria in Solid Tumors.

08:55 EDT Territorial Bancorp trading halted, news pending

08:39 EDT Cardio Diagnostics : PrecisionCHD test may save insurers $13M annually - Cardio Diagnostics Holdings announced the publication of results from a budget impact modeling study for PrecisionCHD , the Company's AI-powered multiomic coronary heart disease detection test. The peer-reviewed study "The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs" published in Advances in Therapy, reported that the use of PrecisionCHD can significantly reduce the cost of secondary prevention for stable coronary heart disease CHD by up to $113.6 million per year for a typical health insurance plan with one million members. PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable CHD. This blood-based test evaluates six DNA methylation and ten genetic biomarkers and uses a proprietary machine learning model to interpret the genetically contextual methylation signals from these biomarkers. The sensitivity and specificity of this test are 79% and 76%, respectively, with the clinical validation study in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics being recently published in the Journal of American Heart Association.

08:36 EDT Omniq announces AI-based vehicle recognition system upgrade at DFW airport - OMNIQ announces a significant upgrade to the parking control system at Dallas Fort Worth International Airport, DFW, an international leader in access solutions and management. After a successful decade of enhancing operational efficiencies at DFW, the third busiest airport in the world, this upgrade represents a renewed commitment to advanced technology and customer satisfaction. The initiative extends the lifespan of the initial investment made by DFW, underscoring the durability and long-term value of OMNIQ's solutions. "This upgrade proves our dedication to improving the airport's setup with new technology," said Shai Lustgarten, CEO of OMNIQ, "It's all about our commitment to providing top-notch solutions that meet our clients' changing needs."

08:34 EDT Atossa announces expanded research agreement with Weill Cornell Medicine - Atossa Therapeutics announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates, ADCs, and (Z)-endoxifen. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The expanded research agreement with Weill Cornell will build on previously conducted in silico research that determined a strong clinically relevant anti-tumor effect when combining ADCs and (Z)-endoxifen. Specifically, the artificial intelligence modeling showed that the combination of (Z)-endoxifen with ADCs will enhance the pro-apoptotic effects seen after administration of either therapy alone. This computer-based analysis was further validated by previously published preclinical studies looking at the effect of selective estrogen receptor modulator (SERM) and chemotherapy combination strategies. Seven key opinion leaders also confirmed the strong scientific rationale and proposed efficacy of combining (Z)-endoxifen with ADCs in patients with advanced breast cancer.

08:31 EDT Biomerica, UAE healthcare company enter exclusive distribution agreement - Biomerica announces a multi-year exclusive distribution agreement with one of the UAE's most substantial healthcare conglomerates. This strategic alliance is set to revolutionize the accessibility and efficiency of colorectal cancer screening and breast examination technologies in the region. Biomerica has entered into a multi-year agreement with a UAE-based multi-billion dollar healthcare powerhouse, commencing with a large initial order for the Company's at-home screening products, EZ Detect and Aware. The partnership will not only enhance the distribution of these innovative health screening tools across the UAE, but also work to engage various governmental health departments in integrating these tests into national health protocols. The collaboration between Biomerica and its UAE partner reflects a shared vision of reducing the burden of cancer through early detection and innovative healthcare solutions. The companies are also exploring opportunities to introduce additional Biomerica products to the UAE, expanding their impact on healthcare improvement.

08:30 EDT Sonoco Products implements price increase for tubes, cores in Mexico - Sonoco announced it is implementing a 6% price increase for tubes and cores products sold in Mexico starting with May 2024 deliveries. "This price adjustment is due to inflationary pressures and increased costs in basic raw materials to produce our products," said Jose Villafana, Vice President/General Manager for Paper Products Latin and South America. "We have postponed this cost increase as long as possible, but market conditions have made this change inevitable. We will continue to monitor the situation closely and take all actions needed to support our customer base with high quality goods and services."

08:28 EDT SAITECH signs MOU with Green Agritech for Canada Manitoba Site Project - SAI.TECH Global announces the signing of a Memorandum of Understanding, MoU, with Green Agritech Ltd. regarding the Company's Canada Manitoba Site Project and the intention of establishing a Joint Venture for the future cooperation. The Project is a 1MW computing data center. It will be implemented through cooperation - between SAI.TECH and Green Agritech Ltd., an innovative crypto mining company. With SAI's unique computing waste heat recovery technology, the heat generated from the computing data center will be recycled and supplied to onsite office and warehouse, and a later constructed greenhouse. The Project also officially marks the Company's entry into the Canadian market of sustainable computing demonstrated by the nature of computing waste heat recycling. Through this project, the Company expects to certify its products for the Canadian market and be ready for its product sale and operation in Canada.

08:24 EDT BioVie awarded up to $13.1M in funding from U.S. DOD to evaluate bezisterim - BioVie announced the grant of a clinical trial award of up to $13.1 million from the U.S. Department of Defense, DOD, awarded through the Peer Reviewed Medical Research Program, PRMRP, of the Congressionally Directed Medical Research Programs, CDMRP. The award can provide up to 2 years of non-dilutive funding for a Phase 2b clinical trial that will assess the Company's anti-inflammatory and insulin sensitizer candidate, bezisterim, for the treatment of neurological symptoms that are associated with long COVID. The Company anticipates the trial to commence by early 2025.

08:23 EDT Soleno Therapeutics receives BTD from U.S. FDA for diazoxide choline - Soleno Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, to diazoxide choline for the treatment of adults and children ages 4 years and older with genetically confirmed Prader-Willi syndrome who have hyperphagia. The designation reflects the Agency's determination that, based on an assessment of the preliminary data from the Phase 3 clinical development program, diazoxide choline may demonstrate substantial improvement on a clinically significant endpoint over available therapies.

08:20 EDT Patria completes acquisition of private equity solutions business from abrdn - Patria Investments confirmed that it has completed the previously announced carve-out acquisition of a private equity solutions business from abrdn. The acquired platform, together with Patria's existing global private markets vehicles, will form a new vertical - Global Private Markets Solutions, with an aggregate Fee Earning AUM of over $10 billion. This vertical will further develop Patria's capabilities to serve clients as a gateway to private markets on a global scale. Marco D'Ippolito, Head of GPMS said: "We are thrilled to bring this transaction to a close and launch this new growth engine for Patria's investment platform. Merrick and his team have built a great business with complementary strategies and a respected track record, and we believe they can thrive in leveraging Patria's platform as we grow together."

08:19 EDT VirTra to introduce V-XR training solution at IAHSS - VirTra announced its participation at the International Association for Healthcare Security & Safety, IAHSS, Conference and Exhibition in Orlando from April 29 to May 1, 2024. As a first-time vendor, VirTra will introduce its new V-XR headset training solution at the event, highlighting its advanced functionality and ability to meet diverse training demands, particularly in healthcare settings. John Givens, CEO of VirTra, stated, "Every day, medical providers around the country go beyond the call of duty for their patients. VirTra supports every initiative within our capabilities to ensure the security of hospital staff while on the job. With our V-XR training solution, we are not only enhancing safety in healthcare environments but also demonstrating its cross-market functionality, allowing us to begin expansion beyond our core law enforcement and military markets. I'm confident that the training provided by our simulators will instill a renewed sense of safety among hospital staff, patients, and their visitors."

08:15 EDT Iterum Therapeutics resubmits NDA to U.S. FDA for oral sulopenem - Iterum Therapeutics announced that it has resubmitted its New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for sulopenem etzadroxil/probenecid for the treatment of uncomplicated urinary tract infections in adult women. "The resubmission of the NDA filing for oral sulopenem is a significant step forward in bringing a new antibiotic to the market for women that suffer from an estimated 40 million uUTIs each year in the U.S.," said Corey Fishman, Chief Executive Officer. "The availability of oral sulopenem, if approved, would mean that physicians and patients have the opportunity to benefit from the proven efficacy and safety of penem antibiotics that, to date in the U.S., have only been available in IV formulations. We look forward to working with the FDA through the review process to advance this much needed treatment option."

08:14 EDT Dayforce appoints Cappellanti-Wolf as EVP, Chief People Officer - Dayforce announced the appointment of Amy Cappellanti-Wolf as EVP and Chief People Officer, effective immediately. Cappellanti-Wolf was most recently Chief Human Resources Officer at Cohesity.

08:12 EDT Collegium Pharmaceutical authorizes generic agreement with Hikma - Collegium Pharmaceutical (COLL) announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals (HKMPF), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta and Nucynta ER in the United States. Under the terms of the agreement: Collegium will manufacture and supply Hikma with all authorized generic product for sale on an exclusive basis during the term of the agreement. Hikma will sell the authorized generic forms of the Nucynta Franchise in the United States, commencing 30 days prior to the anticipated loss of exclusivity for each product, or earlier under certain circumstances. Collegium will receive a meaningful share of net profits of the authorized generic products, that declines based on the number of generic entrants, if any.

08:10 EDT Artivion presents new clinical data for On-X Aortic Heart Valve and AMDS - Artivion announced the presentation of new clinical data from the On-X Low INR post-market study and AMDS PERSEVERE Trial at the 104th American Association for Thoracic Surgery Annual Meeting in Toronto. Presentations highlighted 5-year real-world safety and efficacy data from the On-X Aortic Heart Valve Low INR post-market study that demonstrate even better patient outcomes than predicted by the On-X Aortic Heart Valve PROACT IDE Study, as well as Late-Breaking data from the AMDS PERSEVERE Trial demonstrating, at 30-days post-AMDS implantation, positive aortic remodeling outcomes and zero distal anastomotic new entry tears. Results show a significantly lower composite primary endpoint of thromboembolism, valve thrombosis, and major bleeding of 1.83% vs. the pre-defined historic control rate of 5.39%, driven by an 87% reduction in major bleeding and no increase in thromboembolism compared to historic control group of standard dose warfarin. These real-world interim results confirm that the On-X Aortic Valve remains safe and effective with low-dose warfarin and reflect even better patient outcomes compared to those in the On-X Aortic Heart Valve Low INR Post-Market Study 1-year results presented in 20231, and the On-X Aortic Low INR IDE Study first published in 20142. Early Results of the PERSEVERE Study suggest positive aortic remodeling after treatment with the AMDS Hybrid Prosthesis, as well as no occurrence of distal anastomotic new entry tears.

08:09 EDT Owens Corning announces expiration of HSR Act waiting period for Masonite deal - Owens Corning (OC) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the company's previously announced acquisition of Masonite (DOOR). The expiration of the waiting period occurred at 11:59 p.m. on April 26. The expiration of the HSR Act waiting period satisfies a closing condition for the transaction. Masonite previously announced that its shareholders voted to approve the company's acquisition by Owens Corning at its special meeting of shareholders. The transaction is anticipated to close in May, subject to satisfaction of the remaining customary closing conditions.

08:06 EDT Douglas Elliman in $7.75M settlement pact over 'brokerage commission litigation' - Douglas Elliman announced it has entered into a settlement agreement to resolve on a nationwide basis the pending class action litigation on behalf of sellers relating to real estate brokerage fees in the Gibson and Umpa cases pending in the Western District of Missouri. Under the terms of the settlement agreement, Douglas Elliman has agreed to pay $7.75M within 30 business days of preliminary approval of the settlement by the Court and up to two additional $5 M contingent payments between December 31, 2025 and December 31, 2027.... "Our global network of leading agents and luxury brand continue to position Douglas Elliman for future success as real estate markets stabilize. We remain confident our differentiated business position will enable continued growth over the long term." As part of the settlement agreement, Douglas Elliman has agreed to make certain changes in its underlying business practices. These changes are consistent with the business changes Douglas Elliman's competitors agreed to make in their respective settlements of similar litigation, many of which were already longstanding Douglas Elliman policies. For additional information, the Company has filed a Current Report on Form 8-K with the Securities and Exchange Commission today that includes the settlement agreement. The settlement agreement resolves all claims on a nationwide basis in the Actions and similar claims in other lawsuits alleging claims on behalf of sellers against Douglas Elliman and its subsidiaries and releases the Company, its subsidiaries and affiliated agents from such claims....The settlement agreement remains subject to preliminary and final court approval and will become effective upon final approval by the court.

08:04 EDT Stoke Therapeutics CFO Stephen Tulipano to resign, Thomas Leggett to succeed - Stoke Therapeutics announced the appointment of Thomas Leggett as CFO. In this role, Leggett will be responsible for overseeing all aspects of the company's financial strategy and operations. Leggett succeeds Stephen Tulipano, who resigned his position as Stoke's CFO effective Tuesday, May 7. Leggett brings more than 20 years of experience as a biotechnology executive, board member and as an investment banker. Prior to joining Stoke, Leggett served as CFO at Affinia Therapeutics.

07:56 EDT Fulton Financial buys substantially all assets of Republic First from FDIC - Fulton Financial Corporation (FULT) on Friday announced that its bank subsidiary, Fulton Bank, N.A., acquired substantially all of the assets and assumed substantially all of the deposits of Republic First Bank (FRBK), doing business as Republic Bank, from the Federal Deposit Insurance Corporation. All regulatory approvals, including approval from the Office of the Comptroller of the Currency, have been obtained, and the transaction has closed."With this transaction, we are excited to double our presence across the region," said Fulton Chairman and CEO Curt Myers. During the transition, Republic Bank depositors will continue to have uninterrupted access to their accounts through online banking or by writing checks, using existing ATMs or debit cards. Republic Bank depositors will become Fulton depositors and do not need to change their banking relationship to retain their federally insured deposit insurance coverage. Key transaction terms include: Purchased assets of approximately $6B, including an investment portfolio of approximately $2B and loans of approximately $2.9B. Assumed liabilities of approximately $5.3B, including deposits of approximately $4B and other borrowings and liabilities of approximately $1.3B.

07:44 EDT Zevra Therapeutics issues letter to stockholders on recent accomplishments - Zevra Therapeutics announced that Neil McFarlane, Zevra's President and Chief Executive Officer, has issued a Letter to Stockholders providing a review of key accomplishments and outlook for 2024. "Our Company continues to work through a period of significant growth and transformation with the addition of meaningful new skills and capabilities from the strengths of three companies that have now come together to become One Zevra. Today, I am pleased to share with you a summary of our recent key accomplishments and the reasons for my optimism for 2024 and beyond. We are Building a High-Performance Team... We've Made Significant Progress Advancing our Rare Disease Portfolio... We have a Foundation of Financial Strength... We're Committed to Governance Best Practices... We are Optimistic about Our Future. Bringing it all together, I am confident the opportunities we have in front of us have the potential to deliver meaningful stockholder value... The pace of Zevra's transformation has been tremendous, and I am proud of how much progress we have made. However, there is much more to do. From the combined strength of three teams with diverse experiences and backgrounds, we have become One Zevra, fully focused and dedicated to our mission of bringing life-changing therapeutics to people living with rare disease."

07:41 EDT ICE: Global futures-options markets reached record OI on April 24 up 26% y/y - Intercontinental Exchange announced that its global futures and options markets reached record open interest OI of over 94M contracts on April 24 up 26% year-over-year y/y , including record OI in commodities of 66.3M and record energy OI of 62M , with energy up 30% y/y. "ICE has been focused on building a global commodities and energy trading platform for over two decades, designed to serve the needs of an evolving commercial customer base," said Trabue Bland, SVP, Futures Exchanges at ICE. "The record depths of liquidity truly highlight the benefit our clients are finding in the contracts we provide, that allow for both flexibility and precision hedging across our benchmark derivatives products." ..Across ICE's global environmental complex, open interest is up 43% since the start of the year. The price signals and liquidity provided by ICE's energy and environmental markets are at the heart of helping companies transition to alternative forms of energy by providing tools to allocate capital and manage the associated price risk

07:38 EDT UMB Financial to acquire Heartland Financial in $2B all-stock transaction - UMB Financial (UMBF) and Heartland Financial (HTLF) announced that they have entered into a definitive merger agreement under which UMB Financial will acquire Heartland Financial, in an all-stock transaction valued at approximately $2B. Founded in 1981, HTLF is headquartered in Denver and has $19.4B in assets, $16.2B in total deposits and $12.1B in total loans, as of March 31. This transaction, the largest in UMB's 111-year history, will result in UMB having $64.5B in assets. The transaction will increase UMB's private wealth management's AUM/AUA by 31% and nearly doubles its retail deposit base. It will also add 107 branches and 237 ATMs to UMB's 90 branches and 238 ATMs, expanding the network for both companies' customers. Under the terms of the merger agreement, which were approved by the boards of each company, HTLF stockholders will receive a fixed exchange ratio of 0.55 shares of UMB common stock for each share of HTLF common stock. This per share consideration is valued at $45.74 per share based on UMB's closing price of $83.17 on April 26. Following completion of this contemplated transaction, former HTLF stockholders are expected to collectively represent approximately 31% of the combined company. At the closing of the transaction, five members of the HTLF board will join the UMB board, which will be expanded to 16 members. HTLF has 1,900 associates and UMB has 3,600. Until the transaction closes, the companies will continue to operate independently. The transaction is subject to customary closing conditions, including regulatory approvals and approval by UMB shareholders and HTLF stockholders, and is expected to close in the first quarter of 2025.

07:37 EDT U-Haul Holding Company acquires 3rd self-storage center in Decatur - U-Haul has acquired the former Assured Storage property at 2214 Beltline Road SW in Decatur to better meet the self-storage needs of Morgan County. This is the third U-Haul-owned facility serving the Decatur community. U-Haul intends to hire two new Team Members at the parent store to support the remote facility.

07:35 EDT Intellia Therapeutics to present updated data from Phase 1/2 study of NTLA-2002 - Intellia Therapeutics announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology, EAACI, Congress 2024, taking place May 31 - June 3 in Valencia, Spain. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema, HAE, a rare genetic condition that leads to potentially life-threatening swelling attacks. The presentation will include updated safety and efficacy results from the Phase 1 study across all three dose cohorts.

07:32 EDT New Pacific Metals reports positive Silver Sand metallurgical testing rqesults - New Pacific Metals announced positive results of its metallurgical test program for its Silver Sand project located in Potosi Department, Bolivia. The test program was conducted to meet the standards required for the company's upcoming Preliminary Feasibility Study. Highlights from the test program include: cyanide leach of the first composite sample with 145 g/t head grade, which consisted of 10% Oxide, 80% Transitional and 10% Sulfide, resulted in 92.7% silvery recovery and 1.40 kg/t sodium cyanide consumption1 on average; cyanide leach of the second composite sample with 114 g/t head grade, which consisted of 10% Oxide, 65% Transitional and 25% Sulfide, resulted in 89.6% silvery recovery and 1.10 kg/t sodium cyanide consumption on average; consistent recoveries with the PEA released in January 2023, with the total sodium cyanide consumption being lower than the assumptions made in the PEA; potential for recovery enhancement up to 93.9% for the second composite sample, through gravity concentration and regrinding, to be evaluated before finalizing the PFS. The company remains on track to deliver the results of the PFS in June.

07:23 EDT Philips to pay $1.1B in Respironics settlement - Philips and plaintiffs' leadership have reached an agreement, following a mediation with Judge Diane M. Welsh, to resolve the personal injury litigation and the medical monitoring class action to end the uncertainty associated with litigation in the US. Philips and Philips Respironics do not admit any fault or liability, or that any injuries were caused by Respironics' devices. The settlement addresses the claims filed in the U.S. courts and potential claims submitted to the census registry. Under the settlement, Philips Respironics has agreed to pay a total of $1.1B. The related payments are expected in 2025 and will be funded from Philips' cash flow generation. As a consequence, a EUR 982M provision was recognized in Q1. In April, Philips Respironics signed a consent decree, which was court-approved, and obtained the final court approval for the previously announced economic loss settlement in the U.S., for which a provision was recognized in Q1 2023. Philips also concluded an agreement with insurers to pay Philips EUR 540M to cover Respironics recall-related product liability claims. This income is expected to be recognized in Q2 and payment is expected during 2024. Following the remediation of sleep therapy devices and the reassuring test results to date, these important milestones on litigation, the consent decree and insurance provide Philips with a clear path forward for sustainable value creation.

07:16 EDT Regeneron announces presentations on EYLEA HD, EYLEA Injection at ARVO meeting - Regeneron Pharmaceuticals announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA HD Injection 8 mg. The presentations are part of 14 accepted abstracts on EYLEA HD and EYLEA Injection 2 mg that will be shared at the Association for Research in Vision and Ophthalmology, ARVO, annual meeting from May 5 to 9 in Seattle. Notable podium presentations at ARVO include: One-year data from the PHOTON trial investigating EYLEA HD in diabetic macular edema patients with or without prior treatment, compared to EYLEA. Two-year results from the PULSAR trial investigating EYLEA HD in patients with wet age-related macular degeneration, compared to EYLEA, which will feature a post-hoc analysis on the correlation of key baseline disease characteristics in wAMD to dosing intervals of EYLEA HD. A PULSAR subgroup analysis evaluating visual and anatomic improvements with EYLEA HD, compared to EYLEA, based on baseline best corrected visual acuity, corneal refractive therapy, choroidal neovascularization type and race.

07:14 EDT ProPetro in three year deal with Exxon in Permian, no terms - ProPetro Holding (PUMP) has entered into a three year Hydraulic Fracturing Services Agreement to provide electric hydraulic fracturing services to ExxonMobil (XOM) in the Permian Basin. ProPetro's Chief Executive Officer, Sam Sledge, commented, "We're thrilled to announce a key strategic step for ProPetro as we strengthen our longstanding relationship with ExxonMobil. Having collaborated with them since 2015, our partnership has always been rooted in safety and operational excellence..." ProPetro will deliver and dedicate FORCESM electric-powered hydraulic fracturing fleets to provide fracture stimulation pumping services coupled with our Silvertip wireline and pumpdown services along with other products in connection with such services. The agreement includes the deployment of two FORCESM electric hydraulic fracturing fleets, wireline, and pumpdown services in the first half of 2024 with an option for a third FORCESM fleet with wireline and pumpdown services to commence operations in early 2025. The services are to be delivered over a three-year term with various provisions including performance incentives.

07:12 EDT Amwell releases 2024 Corporate Responsibility Report - Amwell announced the release of its 2024 Corporate Responsibility Report, which details the company's latest progress across environmental, social, and governance topics and highlights Amwell's growing positive impact on key stakeholders and the communities it serves. "Corporate responsibility is fundamental to our mission to transform healthcare, which is facing a worsening environmental footprint, challenging social standards, and an increase in complex regulations," said Ido Schoenberg, M.D., chairman and co-CEO of Amwell. "Our unique position at the center of a powerful and expanding network of health system and health plan clients provides us with a significant opportunity to embed responsible practices into our own business and help drive transformation across the industry to deliver measurable benefits. We're proud to share these results and remain committed to continuous improvement."

07:11 EDT Aquestive Therapeutics receives FDA approval, market access for Libervant - Aquestive Therapeutics announced the U.S. Food and Drug Administration, FDA, has approved Libervant Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients with epilepsy between 2 to 5 years of age. "We are thrilled to have received FDA approval for Libervant in patients between the ages of two and five," said Daniel Barber, Chief Executive Officer of Aquestive. "Patients have been waiting years for Libervant, the first and only FDA approved orally-administered rescue product for the treatment of seizure clusters. Our first priority is to provide and maintain availability of Libervant to the intended patient population. I am pleased to announce that we are currently able to accept and fill non-Medicaid prescriptions. We expect to expand our distribution capabilities over the coming weeks and months. I am also pleased with our continued track record of success with the FDA. We respect the FDA's mission to protect public health and we will always seek to partner with the FDA wherever possible."

07:10 EDT Xtract One awarded U.S. DHS SAFETY Act Designation - Xtract One Technologies announced that the Company's Multi-Sensor-Gateway portfolio, including the SmartGateway and SafeGateway, has been awarded the U.S. Department of Homeland Security, DHS, SAFETY Act Designation as a Qualified Anti-Terrorism Technology, QATT. This award recognizes the Xtract One portfolio for its efficacy in safeguarding public spaces against advanced modern threats and enables Xtract One to bring its innovative security solutions to a larger scale. "We're very grateful to have received the DHS SAFETY Act Designation, another milestone in our mission to bring innovative, advanced weapons detection solutions to a global scale," said Peter Evans, CEO of Xtract One. "This not only validates our technology and enhances trust in our SmartGateway among existing customers, but it also enables us to expand our client base across numerous new venues and organizations. We look forward to continuing to deliver first-class, patron-forward security for everyone walking through our SmartGateway."

07:09 EDT Deciphera to be acquired by ONO Pharmaceutical for $25.60 per share in cash - Deciphera announced that it has entered into a definitive merger agreement with ONO Pharmaceutical, under which ONO will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of ONO, for a total equity value of $2.4B. The boards of directors of both companies have unanimously approved the transaction. Together, ONO and Deciphera will accelerate their shared vision to deliver innovative new drugs and serve patients around the world. Deciphera brings specialized research and development capabilities in kinase drug discovery, well-established commercial and sales platforms in the United States and Europe, and global clinical development capabilities. In addition to Qinlock - Deciphera's switch-control inhibitor for the treatment of fourth-line gastrointestinal stromal tumor, or GIST, which is approved in the United States and over 40 other countries, Deciphera also brings a potential medicines, including vimseltinib, DCC-3116 and multiple additional oncology candidates. The acquisition is structured as a tender offer and subsequent merger of Deciphera with a wholly-owned subsidiary of ONO. Under the terms of the definitive merger agreement, ONO will acquire all outstanding shares of Deciphera for $25.60 per share in cash for a total equity value of approximately $2.4B. The purchase price represents a premium of 74.7% to Deciphera's closing share price of $14.65 on April 26 and a premium of 68.8% to Deciphera's 30-trading-day volume weighted average price as of April 26. ONO will promptly commence the tender offer, and it will expire 20 business days after its commencement, unless otherwise extended. If the tender offer conditions are not satisfied, ONO may be required to extend the tender offer under certain circumstances. Upon the successful completion of the tender offer, ONO's wholly-owned subsidiary will merge with and into Deciphera, with Deciphera continuing as the surviving corporation and a wholly-owned subsidiary of ONO, and any shares of common stock of Deciphera not tendered into the offer will receive the same USD per share price payable in the tender offer. The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions, including U.S. antitrust clearance and the tender of a majority of Deciphera's outstanding shares of common stock. In connection with the execution of the merger agreement, certain stockholders of the company owning approximately 28% of the outstanding shares of Deciphera Common Stock have entered into tender and support agreements pursuant to which they will tender all of their owned shares in the offer. Upon completion of the acquisition, Deciphera will operate as a standalone business of ONO Group, from its headquarters in Waltham, Massachusetts. In light of the acquisition, Deciphera will not host a first quarter 2024 earnings call.

07:07 EDT Arqit Quantum announces collaboration with Intel - Arqit Quantum (ARQQ) announced the creation of the World's First Quantum-Safe, 1.89 Tb IPsec products collaborating with Intel (INTC). Arqit and Intel have joined forces for out-of-the-box post-quantum cryptography solutions using Arqit's Symmetric Key Agreement Platform running on Intel Xeon Scalable processors. Combining Intel technologies with Arqit's SKA-Platform achieves high-performance IPsec encryption, protecting against quantum attacks without compromising speed.

07:06 EDT Globe Life authorizes share repurchases of up to $1.3B - Globe Life authorized share repurchases of up to $1.3B for the two-year period ending December 31, 2025 under the company's existing stock repurchase program.

07:05 EDT NFI Group subsidiary awarded contract for up to 460 BEBs from MBTA - NFI Group announced that the Massachusetts Bay Transportation Authority, MBTA, has awarded NFI subsidiary New Flyer of America a contract for up to 460 next-generation Xcelsior CHARGE NG 40-foot battery-electric transit buses, BEBs. The contract includes a firm order for 80 vehicles, including 48 buses with New Flyer's standard two-door configuration and 32 buses with an additional streetside door for dual-side boarding, plus options for an additional 380 buses.

07:05 EDT Donaldson to acquire 49% stake in Medica, terms undisclosed - Donaldson announced it has entered into a definitive agreement allowing the company to purchase a 49% stake in Medica. Medica is a leader in hollow fiber membrane filtration technology for medical device applications and water purification. Headquartered in Medolla, Italy, the company has over 700 employees globally and generated EUR 80M of revenue in calendar 2023. Founded in 1985, Medica's hollow fiber membrane filtration products are used for blood purification in numerous applications including dialysis, continuous renal replacement therapies, or CRRT, and therapeutic apheresis. The company's products and technologies are also used in the microbiological purification of water, as well as automation solutions for disposable medical device manufacturing. The acquisition is subject, inter alia, to the outcome of the voluntary totalitarian tender offer on the ordinary shares of Medica, which MavenDanc, an Italian company entirely owned by Donaldson, formally announced to the market on the date hereof by way of publication of the communication required by article 102, paragraph 1, of Legislative Decree n. 58 of 24 February 1998. Copy of the 102 Notice is available to the public on Medica website at www.medica-spa.com. Upon positive outcome of the tender offer, Donaldson will acquire a 49% stake of Medica with the option to acquire the remaining 51% stake in the future. Completion of the transaction is expected by the third quarter of calendar 2024. Upon closing, the ratable share of Medica's earnings would be included as a part of the Donaldson Life Sciences segment.

07:04 EDT Cullinan Therapeutics appoints Mary Kay Fenton as Chief Financial Officer - Cullinan Therapeutics announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29. Most recently, Fenton served as Interim Chief Executive Officer and Chief Financial Officer of Talaris Therapeutics.

07:03 EDT LyondellBasell to build integrated plastic waste recycling hub in Germany - LyondellBasell has secured a location for an integrated plastic waste recycling hub south of an existing industrial park in Knapsack, Germany, signing a land lease agreement with YNCORIS GmbH. The hub is planned to combine various advanced sorting and recycling operations, helping to address the plastic waste challenge and grow the circular economy. It is expected that the hub's initial advanced sorting facility will start operations in Q1 2026. These new investments support the company's goal to produce and market at least 2 million metric tons of recycled and renewable-based polymers annually by 2030.

07:02 EDT Lear to acquire WIP Industrial Automation - Lear has entered into a definitive agreement to acquire WIP Industrial Automation, a privately held systems integrator based in Spain that specializes in advanced automation solutions for industrial applications. The transaction, subject to regulatory approvals and other customary closing conditions, is expected to close by Q3. WIP, a Lear supplier with 25 years of automation experience, develops, integrates, and deploys technologies to create customized automation solutions for manufacturing applications. WIP brings strong robotics and AI-based computer vision capabilities to Lear.

07:00 EDT Atea Pharmaceuticals announces presentation on safety profile of bemnifosbuvir - Atea Pharmaceuticals announced the presentation of Phase 1 data highlighting the safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor, at the European Society of Clinical Microbiology & Infectious Diseases Global 2024, which is taking place April 27-30, 2024 in Barcelona, Spain. "The results presented at ESCMID further support the favorable safety profile for bemnifosbuvir by demonstrating the lack of cardiotoxicity in healthy participants," said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. "Our goal is to address the substantial unmet need for the treatment of COVID-19 and hepatitis C virus (HCV), which continues due to the limitations of available treatments. During the second half of 2024, we look forward to reporting results for bemnifosbuvir from our Phase 3 SUNRISE-3 trial for COVID-19 and results for the combination of bemnifosbuvir and ruzasvir from our Phase 2 trial for HCV."

06:57 EDT Norfolk Southern comments on Ancora MOU with BLET - Norfolk Southern issued the following statement after being made aware that Ancora has, without any authority or authorization, negotiated and signed a memorandum of understanding with The Brotherhood of Locomotive Engineers and Trainmen, or BLET, a division of the International Brotherhood of Teamsters. The company said this unauthorized agreement purports to offer specific concessions by Norfolk Southern to the BLET in exchange for the BLET's support of Ancora's attempt to gain control of the company's board. Norfolk Southern commented: "Ancora, a shareholder in Norfolk Southern with no authority whatsoever to enter into any current or future binding agreement on behalf of the company, has negotiated and signed a memorandum of understanding with the BLET that commits its director nominees to future actions if they gain control of the board. Ancora's actions are a blatant attempt to buy votes through backdoor deals to take control of the company. This desperate effort by Ancora, if successful, provides concessions to the BLET that limit operational flexibility and destroy significant value for the company. Aside from violating the Railway Labor Act rules that grant exclusive negotiating authority to representatives of Norfolk Southern, Ancora has demonstrated that its own nominees are not independent and are beholden only to Ancora. Clearly, Ancora is willing to take any steps to get its nominees elected to the board, including making unauthorized commitments to Norfolk Southern's employee unions to cover up its own management candidates' abhorrent track record with labor. Together with our unions, Norfolk Southern has made significant progress to create a safer, more productive railroad. Unions representing the majority of our craft workers have publicly supported our strategy and raised concerns about the dangers of Ancora's plan. We remain focused on responsibly improving our operational performance, employees' quality of life and working environment. In contrast, Ancora is misleading shareholders and employees with false promises and unauthorized financial commitments that would destroy shareholder value."

06:55 EDT Norfolk Southern shareholder Ancora's nominees recommended by Glass Lewis - Norfolk Southern shareholder Ohio-based Ancora Holdings, which owns a large equity stake in Norfolk Southern, announced that proxy advisory firm Glass Lewis recommends the company's shareholders vote to elect six dissident nominees on the Blue Proxy Card at the upcoming Annual Meeting of Shareholders on May 9. In particular, Glass Lewis recommends for the following Ancora nominees: Betsy Atkins, James Barber, Jr., William Clyburn, Jr., Sameh Fahmy, Gilbert Lamphere and Allison Landry. In its report, Glass Lewis noted the following regarding the need for change at Norfolk Southern: "...we believe Ancora has presented a compelling case for supporting a substantial overhaul of the Company's current leadership." "Based on our review, we believe the operating performance of the company has been consistently worse than its peers for an extended period." "We are also inclined to agree with Ancora's critique of the company's current operating strategy as being one that relies on inherently incompatible railroading concepts." "[I]t's not readily evident to us the Company's current leadership had built up a sufficiently positive track record such that investors might reasonably have the patience to allow management to implement a relatively novel operating strategy." "We also believe that Ancora's candidates for the Company's top executive roles - James Barber, Jr. as CEO and Jamie Boychuk as COO - have compelling credentials and track records."

06:52 EDT JinkoSolar sees Q2 module shipments 24GW-26GW

06:47 EDT Iris Energy operating hashrate has increased to 9 EH/s - IREN provided a business update. IREN is pleased to announce that its expansion is ahead of schedule and operating hashrate has increased to 9 EH/s. The company now also expects to achieve 10 EH/s in May 2024. IREN's fully funded expansion to 20 EH/s in 2024 remains on track, which will improve nameplate fleet efficiency to 21.9 J/TH. Furthermore, the company now expects to commission an additional 50MW of data center capacity as part of Childress Phase 3 this year. This increases planned data center capacity from 460MW to 510MW by the end of 2024. The additional 50MW of capacity has been enabled partly through a new substation design, as well as ongoing improvement and optimization of the Company's construction and procurement process.

06:37 EDT Daqo New Energy sees Q2 polysilicon production 60,000MT-63,000MT - The company said, "The Company expects to produce approximately 60,000MT to 63,000MT of polysilicon during the second quarter of 2024. The Company expects to produce approximately 280,000MT to 300,000MT of polysilicon for the full year of 2024, inclusive of the impact of the Company's annual facility maintenance. This outlook reflects Daqo New Energy's current and preliminary view as of the date of this press release and may be subject to changes. The Company's ability to achieve these projections is subject to risks and uncertainties. See "Safe Harbor Statement" at the end of this press release."

06:31 EDT AstraZeneca reports results from DESTINY-Breast06 Phase 3 trial - Positive high-level results from the DESTINY-Breast06 Phase III trial showed that Enhertu demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, or PFS, compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy, AstraZeneca announced. A statistically significant and clinically meaningful improvement in PFS was also observed in the overall trial population. A prespecified subgroup analysis showed the clinically meaningful improvement was consistent between patients with HER2-low and HER2-ultralow expression. Overall survival, or OS, data were not mature at the time of the analysis; however, Enhertu showed an early trend towards an OS improvement versus standard-of-care chemotherapy in patients with HER2-low metastatic breast cancer and in the overall trial population. The trial will continue as planned to further assess OS and other secondary endpoints. Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "DESTINY-Breast06 shows that Enhertu could become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy. These data underscore the potential for treatment with Enhertu across the spectrum of HR-positive breast cancer, further redefining the treatment of metastatic breast cancer."

06:27 EDT Parsons wins position on $464M Army site remediation contract - Parsons was awarded a position on an indefinite-delivery, indefinite-quantity multiple award task order contract by the Army Environmental Command for remediation services at sites involving hazardous toxic waste, including perfluoroalkyl and polyfluoroalkyl substances. The $464M ceiling value contract consists of a five-year ordering period and is new work for the company. Under this contract, Parsons will compete for task orders to perform evaluation, investigation, and other remediation services at various U.S. Army installations throughout the country and territories. Activities include PFAS treatment, munitions response, and operational range assessments.

06:19 EDT AstraZeneca reports Truqap plus Faslodex recommended for EU approval by CHMP - AstraZeneca's Truqap in combination with Faslodex has been recommended for approval in the European Union for the treatment of adult patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN-alterations following recurrence or progression on or after an endocrine-based regimen, AstraZeneca reported. The Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency based its positive opinion on the results from the CAPItello-291 Phase III trial published in The New England Journal of Medicine, the company stated.

06:15 EDT Hipgnosis Songs Fund agrees to $1.6B cash offer from Blackstone - The board of Hipgnosis Songs Fund announced on Monday that it is backing a cash offer from Blackstone of $1.30 a share, up from the buyout group's initial proposal of $1.24 a share made last week. The Acquisition values Hipgnosis' entire issued, and to be issued, ordinary share capital at approximately $1.6B. "The breadth of the Blackstone platform, combined with our operational expertise, will support and enhance the value of the acquired rights," Hipgnosis said in a statement. Reference Link

06:08 EDT Alliance Resource Partners sees 2024 total sales of 34-35.8 tons - Sees 2024 total coal sales price $61.75-$63.75 per ton. Sees 2024 total capital expenditures $450M-$500M.

06:06 EDT Enerflex prevails in appeal of Mexican Labor Board decision - Enerflex provided an update with regard to an ongoing legal proceeding in Mexico. The Tenth Circuit Collegiate Court on Labor Matters in Mexico has published a decision setting aside a January 31, 2022 decision of a Labor Board in the State of Tabasco, Mexico that had ordered subsidiaries of Exterran Corporation to pay a former employee approximately $125M plus other benefits in connection with a dispute relating to the employee's severance pay following termination of his employment in 2015. In rendering its decision, the Court ruled in favor of Enerflex's arguments that the Labor Board ruling was in error and had no credible basis in law or fact. The matter has now been returned to the Labor Board to issue a new judgement in accordance with the Court's ruling and directives, which support the company's view that the Labor Board's ultimate resolution will be immaterial to its financial results.

05:18 EDT Addex says ADX71149 didn't achieve statistical significance for primary endpoint - Addex Therapeutics announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam. The Phase 2 study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care. The data were reported from a total of 110 evaluable patients, who each received either 50 mg or 100 mg of ADX71149 twice daily in addition to their standard dose of levetiracetam or brivaracetam and up to three other anti-seizure drugs. Adjunctive administration of ADX71149 was safe and well tolerated.

05:05 EDT Paysafe launches Pay by Bank for iGaming - Paysafe launched Pay by Bank for iGaming, a new solution allowing U.S. online bettors to instantly and securely fund deposits at operators' cashiers directly from their online bank account as well as cash-out winnings seamlessly. This product expands the capabilities of Paysafe's Gateway, the iGaming payments solution that connects U.S. operators to the market's most comprehensive range of traditional and alternative payment methods via a single integration.